Navigation Links
Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile
Date:9/23/2010

NEW YORK, Sept. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Eli Lilly & Co.: PharmaVitae Profile

http://www.reportlinker.com/p0201761/Eli-Lilly--Co-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Eli Lilly in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial per

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Eli Lilly: PharmaVitae forecasts at a glance 8

Strategic insight 9

The looming challenge of 'Years Y and Z' 9

Strategies to weather the loss of sales 10

Investment following 'Year X' 10

Looking to external sources of growth 11

Outlook heavily dependent upon Effient and Byetta LAR 12

Out-sourcing spreads risk and leverages expertise 15

SWOT analysis 16

Strengths 17

Weaknesses 18

Opportunities 19

Threats 21

Table of Contents 22

Table of figures 24

Chapter 3 Quarterly news update 25

Key findings 25

Product developments 26

Deals and alliances 27

Product deals 27

Technology deals 27

M&A activity 27

Company announcements 28

Future product milestones 29

Chapter 4 Company introduction 30

Key findings 30

Background 31

Key corporate developments 31

M&A history 32

Advanced Cardiovascular Systems acquired 32

Hybritech acquired 32

DowElanco formed 33

Devices for Vascular Intervention acquired 33

Origin Medsystems acquired 33

Sphinx Pharmaceuticals acquired 33

Guidant spun-out 33

Remaining medical device businesses divested 33

PCS Health Systems acquired 33

Hybritech divested 34

DowElanco holding sold 34

PCS Health Systems sold 34

Applied Molecular Evolution acquired 34

ICOS acquired 34

Hypnion acquired 34

Ivy Animal Health acquired 34

SGX Pharmaceuticals acquired 34

ImClone Systems acquired 35

M&A strategy 35

Current corporate structure 36

Pharmaceuticals 37

Elanco Animal Health 37

Pharmaceuticals business unit structure 38

Chapter 5 Company sales 39

Key findings 39

Prescription pharmaceutical sales and growth rate analysis, 2002-14 40

Product analysis 42

Product analysis, 2002-08 43

Product analysis, 2008-14 45

Therapy area analysis 49

Geographic analysis 53

Launch/core/expiry analysis 55

Explanation of launch/core/expiry analysis 55

Launch analysis, 2008-14 56

Core analysis, 2008-14 60

Expiry analysis, 2008-14 62

Launch/core/expiry configuration, 2008-14 64

Molecule type analysis 65

Externalization analysis 67

Chapter 6 Company financials 69

Key findings 69

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 70

Operating costs and profit analysis 72

Operating costs and profit analysis, 2002-08 73

Operating cost ratio and profit margin analysis, 2002-08 75

Operating cost ratio and profit margin analysis, 2008-14 76

Operating costs and profit analysis, 2008-14 77

Chapter 7 Key products and competitors 79

Key findings 79

Overview 80

Central nervous system 81

Zyprexa 81

Overview 81

Sales forecast 82

Sales have slipped due to side effect concerns 82

Further gradual decline before US generics in 2011 82

Zypadhera delayed by side effect issues 83

Cymbalta 84

Overview 84

Sales forecast 85

Commercial success despite competition from Effexor and generic selective serotonin reuptake inhibitors (SSRI) 85

New indications have significantly lifted sales 85

Key growth driver to turn to decline in 2013 86

dirucotide (MBP-8298) 87

Overview 87

Sales forecast 88

Multiple sclerosis candidate in-licensed from BioMS 88

Disappointment in relapsing-remitting multiple sclerosis 88

Focus on a genetic subset of patients with secondary progressive multiple sclerosis 89

Results from the MAESTRO Phase III program will clarify commercial potential 89

Endocrine, metabolic & genetic disorders 91

Byetta franchise 91

Overview 91

Sales forecast 92

First integrin mimetic to market 92

Competition challenges sales growth 93

Byetta LAR offers once-weekly convenience 93

Humalog franchise 94

Overview 94

Sales forecast 95

Insulin is the cornerstone of diabetes treatment 95

New Humalog formulations have driven further market expansion 95

Market leading position lost to new entrants 95

Scope for further growth is limited 96

Humulin franchise 98

Overview 98

Sales forecast 99

Move away from human insulins 99

Sales supported by market dynamics 99

Oncology 100

Alimta 100

Overview 100

Sales forecast 101

Indication expansion has driven growth 101

Further approvals will lift sales 102

Growth maintained across 2008-14 102

Gemzar 103

Overview 103

Sales forecast 104

Approval in additional indications has driven sales growth 104

Forecast dominated by impact of generic erosion 105

Erbitux 106

Overview 106

Sales forecast 107

The acquisition of ImClone Systems brought Eli Lilly rights to Erbitux 107

Mechanism of action facilitates indication expansion 107

Cardiovascular 109

Effient (prasugrel) 109

Overview 109

Sales forecast 110

Effient offers superior efficacy at the cost of bleeding 110

Regulatory and competitive threats to forecast sales 110

Genitourinary 111

Evista 111

Overview 111

Sales forecast 112

Chapter 8 Appendix 113

R&D pipeline 113

Collaboration/ other revenue reconciliation 116

2002-08 116

2008-14 117

References 117

Abbreviations 118

Exchange rates 119

About Datamonitor 120

About Datamonitor Healthcare 120

Datamonitor consulting 120

Disclaimer 122

List of Tables Table 1: Eli Lilly - PharmaVitae forecasts at a glance 8

Table 2: Eli Lilly key product developments, Q1-Q2 2009 26

Table 3: Eli Lilly product deals and alliances, Q1-Q2 2009 27

Table 4: Eli Lilly technology deals and alliances, Q1-Q2 2009 27

Table 5: Eli Lilly M&A activity, Q1-Q2 2009 27

Table 6: Eli Lilly company announcements, Q1-Q2 2009 28

Table 7: Eli Lilly future product milestones, 2009-11 29

Table 8: Eli Lilly product portfolio overview ($m), 2002-08 43

Table 9: Eli Lilly product portfolio overview ($m), 2008-14 45

Table 10: Eli Lilly prescription pharmaceutical sales by therapy area ($m), 2008-14 52

Table 11: Eli Lilly prescription pharmaceutical sales by geographic region ($m), 2008-14 54

Table 12: Eli Lilly launch portfolio overview ($m), 2008-14 56

Table 13: Eli Lilly core portfolio overview ($m), 2008-14 60

Table 14: Eli Lilly expiry portfolio overview ($m), 2008-14 62

Table 15: Eli Lilly prescription pharmaceutical sales by molecule type ($m), 2008-14 66

Table 16: Eli Lilly prescription pharmaceutical sales by source ($m), 2008-14 68

Table 17: Total Eli Lilly sales by business unit ($m), 2002-08 70

Table 18: Eli Lilly operating revenue/cost analysis ($m), 2002-08 73

Table 19: Eli Lilly operating cost ratio analysis (% of total revenues), 2002-08 75

Table 20: Eli Lilly operating cost ratio analysis (% of total revenues), 2008-14 76

Table 21: Eli Lilly operating revenue/cost analysis ($m), 2008-14 77

Table 22: Key products overview 80

Table 23: Zyprexa: overview 81

Table 24: Zyprexa: sales forecast ($m), 2008-14 82

Table 25: Cymbalta: overview 84

Table 26: Cymbalta: sales forecast ($m), 2008-14 85

Table 27: dirucotide: overview 87

Table 28: dirucotide: sales forecast ($m), 2008-14 88

Table 29: Byetta: overview 91

Table 30: Byetta franchise: sales forecast ($m), 2008-14 92

Table 31: Humalog franchise: overview 94

Table 32: Humalog franchise: sales forecast ($m), 2008-14 95

Table 33: Humulin franchise: overview 98

Table 34: Humulin franchise: sales forecast ($m), 2008-14 99

Table 35: Alimta: overview 100

Table 36: Alimta: sales forecast ($m), 2008-14 101

Table 37: Gemzar: overview 103

Table 38: Gemzar: sales forecast ($m), 2008-14 104

Table 39: Erbitux: overview 106

Table 40: Erbitux: sales forecast ($m), 2008-14 107

Table 41: Effient: overview 109

Table 42: Effient: sales forecast ($m), 2008-14 110

Table 43: Evista: overview 111

Table 44: Evista: sales forecast ($m), 2008-14 112

Table 45: Eli Lilly's R&D pipeline (Phase I-registration) 113

Table 46: Total Eli Lilly sales by business unit ($m), 2002-08 116

Table 47: Total Eli Lilly sales by business unit ($m), 2008-14 117

Table 48: Exchange rates, 2009 119

List of Figures Figure 1: The PharmaVitae Explorer 3

Figure 2: Eli Lilly prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Eli Lilly's financial performance ($m), 2002-14 7

Figure 4: Impact of 'Year XYZ' expiries on Eli Lilly's total pharmaceutical sales 9

Figure 5: Eli Lilly year-on-year pharmaceutical revenue growth split by source, 2008-14 11

Figure 6: Sensitivity of Eli Lilly's pharmaceutical revenue outlook on key assumptions 13

Figure 7: Eli Lilly SWOT analysis 16

Figure 8: M&A/divestment history 32

Figure 9: Current corporate structure 36

Figure 10: Current corporate structure 36

Figure 11: Pharmaceuticals business unit structure 38

Figure 12: Eli Lilly prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 40

Figure 13: Key product sales ($m), 2002-14 42

Figure 14: Eli Lilly key sales growth drivers and resistors ($m), 2002-08 44

Figure 15: Eli Lilly key sales growth drivers and resistors ($m), 2008-14 47

Figure 16: Eli Lilly prescription pharmaceutical sales by therapy area ($m), 2002-14 49

Figure 17: Eli Lilly prescription pharmaceutical sales by geographic region ($m), 2002-14 53

Figure 18: Eli Lilly launch/core/expiry configuration ($m), 2008-14 64

Figure 19: Eli Lilly prescription pharmaceutical sales by molecule type ($m), 2002-14 65

Figure 20: Eli Lilly prescription pharmaceutical sales by source ($m), 2002-14 67

Figure 21: Eli Lilly operating revenue/cost analysis ($m), 2002-14 72

To order this report:Pharmaceutical Industry: Eli Lilly & Co.: PharmaVitae Profile

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
2. Reportlinker Adds The Impact of US Healthcare Reform on Pharma: Analyzing the Effects
3. Reportlinker Adds IP Overview - "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010
4. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
5. Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
6. Reportlinker Adds U.S. Market for Cardiac Rhythm Management, Electrophysiology and Ablation Devices 2010
7. Reportlinker Adds Canadian Dental Market Overview & Dentist Survey 2010 (Implants, Prosthetics, Imaging & CAD/CAM)
8. Reportlinker Adds ENT Devices Market Outlook in Argentina to 2016 - Hearing Aid Devices and Implants and Diagnostic Devices
9. Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems
10. Reportlinker Adds Interventional Cardiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
11. Reportlinker Adds Clinical Trial Patient Recruitment: Accelerate Enrollment, Increase Retention and Reduce Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... SUNNYVALE, Calif. , Feb. 10, 2016 /PRNewswire/ ... Warren Kocmond , formerly Executive Vice President ... the position of President and Chief Operating Officer.  ... been expanded, and now include Global Commercial Operations ... and Customer Service.  Mr. Kocmond will continue to ...
(Date:2/10/2016)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced ... full year ended December 31, 2015. ... year for Vanda with the continued growth of HETLIOZ ... HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., Vanda,s ... U.S. product portfolio builds on this success and underscores ...
(Date:2/10/2016)... LEXINGTON, Massachusetts , February 10, 2016 --> ... Japan .  --> Japan .  ... Japan .  With submission, Shire continues to ... --> With submission, Shire continues to ... With submission, Shire continues to strengthen ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to stabilize critical ... leave patients with dental emergencies at risk of losing a tooth or their smiles. ... , Common dental emergencies include:, , Avulsed or knocked-out ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ... Care Association™ (ALCA) to conduct a survey that takes a closer look at cases ... illustrates the prevalence and causes of TBI among the aging population, and identifies the ...
(Date:2/10/2016)... ... 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused ... full year ended December 31, 2015 on Monday, February 29, 2016 after the market ... community following the release at 4:30 PM ET. Investors interested in participating by phone ...
(Date:2/10/2016)... ... ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves with age, ... Guide to Brain Training" by award-winning author Phyllis Strupp explains how brain ... 16, 2016. A free review copy is available to the media at NetGalley ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX Health & ... PEEK-lined stainless steel (PLS) columns combine the strength of traditional stainless steel with ... of biological samples while operating at ultra-high pressures of 20,000 psi. The higher ...
Breaking Medicine News(10 mins):